MissionIR Articles

Cardium Therapeutics is implementing a broad-based strategy of engaging the medical and health marketplace, focused on opportunities offering a clear path to monetization. Generx, Cardium’s lead clinical development product candidate, is unique in its ability…

Today before the bell, Cardium Therapeutics announced that it has received ISO 13485:2003 certification for its Excellagen® advanced wound care product by BSI, one of the world’s leading certification bodies. This certification is a stand-alone…

Earlier today, Cardium Therapeutics announced that its To Go Brands® division has expanded its VitaRocks® kids vitamins product line and that retail distribution of the newly-designed products is being been expanded to include select Target…

Coronary artery disease – the No. 1 cause of death worldwide – kills more than 17 million people around the world each year. It’s easy to skim over the statistics when “death” dominates global headlines.…

Cardium Therapeutics’ lead clinical development product candidate is Generx, a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. Unlike other coronary drug therapeutics, Generx is…

Today before the opening bell, Cardium Therapeutics announced that the American Podiatric Medical Association (APMA) has granted its prestigious Seal of Approval to Excellagen®, Cardium’s advanced, FDA-cleared wound care product, for improving foot health and…

Cardium Therapeutics has a capital-efficient, asset-based business strategy focused on building a diversified portfolio of new and innovative bio-medical product opportunities and businesses, leveraging research and development investments by big pharma, venture, and institutional investors.…

Today before the opening bell, Cardium Therapeutics announced its Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D. delivered a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The presentation,…

Cardium Therapeutics is a health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative health products. As an important part of its overall strategy, the company has entered the health…

One of the challenges of every parent is ensuring that their children get the kind of nutrition they need. You can avoid keeping junk foods around the house, and make a point of serving vegetables…

When health sciences and regenerative medicine company Cardium Therapeutics made their presentation recently at the Biotech Showcase Conference in San Francisco, they summarized their unique collection of technology platforms, detailing respective market potential and plans…

Today before the opening bell, Cardium Therapeutics announced it has entered a distribution agreement with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare…

When Cardium Therapeutics recently acquired To Go Brands, a San Diego based nutraceuticals developer, it was a major expansion of Cardium’s original Medpodium nutraceutical line, and reflective of the company’s support for the nutraceutical side…

A major part Cardium’s product candidate portfolio, and the company’s overall strategy, is Excellagen, an acellular biological modulator for advanced wound care management. Cardium’s strategic goal is to develop a portfolio of medical product candidates…

Nutraceuticals developer To Go Brands, recently acquired by health sciences company Cardium Therapeutics, is focused on bringing 100% natural nutrition to people on the go, which includes just about everyone. Their products are designed for…

In October of 2012, Cardium Therapeutics, a health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative health products, acquired To Go Brands, a developer of easy-to-use nutraceuticals. To Go…

Excellagen, Cardium’s FDA-cleared highly-refined fibrillar collagen-based topical gel designed to facilitate wound care management for diabetic ulcers and many other types of wounds, has been the center of much of Cardium’s recent activity. The product…

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, today announced it was on the winning side of a patent decision made in Europe. This decision resolved a long-standing competition between Cardium and its…

Cardium Therapeutics, a health sciences and regenerative medicine company, today presented financial results for the third quarter, ended September 30, 2012. The company also reported on recent developments, including the acquisition of To Go Brands…

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, announced this morning that the company will be displaying two Excellagen® poster presentations at the Desert Foot 2012 High Risk Diabetic Foot Conference being held…